Merck's Growth Masks Underlying Issues, Analysts Warn

Merck's recent stock price surge has left investors wondering whether to hold onto their shares or sell. Over the past six months, Merck's stock price has climbed to $149.98, representing a 29.6% increase and outperforming the S&P 500 by 13.4%. However, despite this impressive growth, analysts are cautioning against investing in the company due to several red flags.

One concern is Merck's weak constant currency revenue growth, which has averaged only 3.8% year-over-year over the last two years. This performance lags behind the sector and suggests that the company may need to lower prices or invest in product improvements to accelerate growth - factors that can hinder near-term profitability.

Another issue is Merck's shrinking adjusted operating margin, which has decreased by 19.9 percentage points over the last five years. This raises questions about the company's expense base and its ability to maintain profitability as revenue grows.

Finally, analysts point out that Merck's earnings per share have been trending downward, declining by 11.1% annually over the last five years despite revenue growth of 7.9%. This suggests that the company is becoming less profitable on a per-share basis as it expands.